新药审批金赛药业 GS3-007a11月17日,金赛药业宣布其自主研发的口服小分子生长激素促分泌药物GS3-007a干混悬剂获批临床,将开展用于生长激素缺乏症所致的儿童生长缓慢(PGHD)的临床试验,成为国内首个进入临床的口服生长激素分泌素受体1a (GHSR-1a)小分子激动剂。11月18日,金赛药业宣布旗下自主研发的新型靶向叶酸受体α亚型(Folate Receptor Alpha, FRα/...
Source Link新药审批金赛药业 GS3-007a11月17日,金赛药业宣布其自主研发的口服小分子生长激素促分泌药物GS3-007a干混悬剂获批临床,将开展用于生长激素缺乏症所致的儿童生长缓慢(PGHD)的临床试验,成为国内首个进入临床的口服生长激素分泌素受体1a (GHSR-1a)小分子激动剂。11月18日,金赛药业宣布旗下自主研发的新型靶向叶酸受体α亚型(Folate Receptor Alpha, FRα/...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.